AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01655641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Drug: Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV For non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
Study NCT01655641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Includes routine surgical care involved in preventing blood loss during and after surgery.
Study NCT02762136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02762136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xiang-sha-liu-jun granules
Description: The Xiang-sha-liu-jun granules comprises 10 herbs, Astragalus membranaceus (Huangqi) 15g, Codonopsis pilosula (Dangshen) 15 g, fructus aurantii (Zhiqiao) 15g, fructus amomi(Sharen) etc
Study NCT04685369 — intervention group
Intervention type: OTHER
Intervention: Medical Data extraction
Description: Medical Data extraction
Study NCT00757081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phosphatidylcholine and deoxycholate
Description: 50 mg phosphatidylcholine, 42 mg deoxycholate subcutaneous injection Every 8 weeks x 2 with additional 2 treatments optional
Study NCT03605836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine SR
Description: 100 mg, BID, oral tablets
Study NCT03605836 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID, oral tablet
Study NCT03605836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BID, oral tablet
Study NCT03605836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine SR
Description: 200 mg, BID, oral tablets
Study NCT00964639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: During the surgery infiltration with Naropine 2 mg/ml. The dosage in the infiltration is 2 mg/kg. Thereafter bolus 3 times a day
Study NCT00964639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: During the surgery infiltration with saline. Thereafter bolus 3 times a day
Study NCT02095249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pimonidazole
Description: Pimonidazole is to be administered to patients scheduled for radical prostatectomy one day prior to surgery.
Study NCT02216292 — intervention group
Intervention type: OTHER
Intervention: Control Group
Description: Infants received preterm formula during their first days of life until breastmilk from their own mother was available
Study NCT02216292 — intervention group
Intervention type: OTHER
Intervention: Preterm Single Donor Milk Group
Description: Infants received preterm single donor milk during their first days of life until breastmilk from their own mother was available
Study NCT00634751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.
Study NCT00634751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.
Study NCT00634751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).~Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length~Sorafenib 200 mg BID Oral Daily Every 28 days~If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.~Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length~Sorafenib 400 mg BID Oral Daily Every 28 days
Study NCT04003051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02272244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support & Navigation
Study NCT02272244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Study NCT02845440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Academic Detailing
Description: Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. AD helps clinicians understand and adopt targeted evidence-based practices and is one of the few Continuing Medical Education (CME) interventions that has consistently demonstrated improved alignment of physician prescribing behavior with evidence-based practice.
Study NCT02845440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: Community Health Worker (CHW) The CHW will offer to support patients and prescribers in health promotion and preventive care in general and specifically to support communication between the primary care provider and patient regarding smoking status, smoking cessation, and to aid implementation of any smoking cessation treatments recommended by prescribers. CHWs will complete the standard CHW certificate training program in general preventive medicine, available through the Boston Public Health Commission. CHWs will then receive the additional specialized training.
Study NCT02845440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services.
Study NCT03422757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adaptive Deep Brain Stimulation
Description: The investigational medical device (AlphaDBSvext) is a portable, external, dual mode stimulator that can deliver adaptive DBS or conventional DBS for the treatment of PD.~In the adaptive mode, the device records Local Field Potential activity from the implanted DBS electrode and simultaneously delivers stimulation through the same electrode based on the recorded signal.
Study NCT03422757 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional Deep Brain Stimulation
Description: The same investigational medical device (AlphaDBSvext) is used to deliver conventional DBS for the treatment of PD. In the conventional mode it delivers constant stimulation.
Study NCT00926562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopromide (Ultravist)
Description: Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
Study NCT00926562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol (Visipaque)
Description: Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
Study NCT03316742 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Intervention 1 includes providing participants with a high fiber food product, protein source, high intensity sweetener and adult multivitamin.
Study NCT03316742 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: Intervention 2 includes providing participants with an alternative dietary fiber source, milk protein, high intensitysweetener and adult multivitamin.
Study NCT03187795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride IR
Description: Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
Study NCT04458532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: 300 min/wk for 16 weeks
Study NCT04458532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: 150 min/wk for 32 weeks
Study NCT04458532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: 300 min/wk for 32 weeks
Study NCT04458532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training
Description: 150 min/wk for 16 weeks
Study NCT03393897 — intervention group
Intervention type: OTHER
Intervention: Trans oesophageal echocardiography
Description: Transoesophageal echocardiography : it's a standard practice for this patient
Study NCT03393897 — intervention group
Intervention type: OTHER
Intervention: Trendelenburg test
Description: Trendelenburg test : it's a standard practice for this patient
Study NCT03931382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Simulator
Description: The VR intervention is underpinned by experiential learning and social cognitive theory, such that user will observe successful performance and simulation to encourage imitation and reinforce success in the assessment. All participants will be undergoing a simulation assessment with the head coil.
Study NCT03931382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mock MRI Simulator
Description: The mock MRI is provided by the Child Life Specialist, according to the current care plan which consists of exposing children to the MRI simulator, medical devices, and procedures. The mock MRI is located within the medical imaging facility. All participants will be undergoing a simulation assessment with the head coil.
Study NCT03931382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Preparation Manual
Description: The standard MRI preparation manual provides access to a series of printed photos and text showing the MRI experience step-by-step to help prepare for MRI. All participants will be undergoing a simulation assessment with the head coil.
Study NCT04975659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and Nocebo effect
Description: Positive suggestion and words is used on Placebo group Negative suggestion and words is used on Nocebo group
Study NCT04975659 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Nocebo effect
Description: Positive suggestion and words is used on Placebo group Negative suggestion and words is used on Nocebo group
Study NCT01819571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid loading (Voluven)
Description: HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
Study NCT03419637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: The mobile app, or app, is installed on the patient's mobile device and is used to document the surgical procedure with before and after photographs, including pre- and post-surgery diagnosis. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
Study NCT04642118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary recruitment maneuver
Description: Using setting pressure form ventilator to increase pulmonary pressure by compress balloon bag 5 times, 5 seconds per time
Study NCT03187795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
Study NCT05431231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Outcome Questionnaire-45
Description: a questionnaire that evaluates the patient's level of distress. The questionnaire was developed by Lambert et al. in 1996 and was translated to Hebrew by Gross, Glasser, Elisha et al. in 2015. The questionnaire is composed of 45 statements that describe emotional states, assessing three main components: subjective discomfort, interpersonal relationships and performance of social roles. The participants are asked to rate how often they have felt the states described by each statement using a five-level Likert scale (0 - never, 4 - almost always). This questionnaire has been used extensively and has showed good internal consistence of 0.93 for its English version and 0.91 for its Hebrew version.
Study NCT05431231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hopkins symptoms checklist - short form
Description: a questionnaire for assessing symptomatic distress. The questionnaire was developed by Lutz, Tholen, Schürch, and Berking in 2006. It is a short version of the SCL-90-R, that was developed by Derogatis in 1992. The checklist includes 11 items that describe negative feelings and thoughts. Participants are asked to rate the extent to which a given feeling or thought has troubled them in the past week using a four-level Likert scale (1 - not at all, 4 - very much). This tool is highly correlated with the Global Severity Index (r=.91) and has shown high internal consistency.
Study NCT05431231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prodromal Questionnaire - Brief Version
Description: a patient questionnaire that assesses the existence of a prodromal state or fully developed psychosis. It was developed by Ising et al. in 2012 and was translated to Hebrew by Koren et al. in 2016. The tool is based on a more extensive questionnaire - PQ-92 - that was developed by Loewy et al. in 2005 - and constitutes an attempt to create an improved shorter version. The PQ-16 includes 16 items that refer to thoughts, feelings and experiences that describe various symptoms, including abnormal perception (9 items), unconventional thinking and paranoia (5 items) and negative symptoms (2 items). For each item, first, the participant is asked to indicate whether he had experienced that phenomenon in the past month, and if he had, he is asked to describe the extent to which the phenomenon had caused him distress, using a four-level Likert scale (0 - no distress, 3 - severe distress). Ising et al. found that Kronbach's α was 0.774 for the whole questionnaire.
Study NCT03960203 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: InSight
Description: Clinical decision support (CDS) system for severe sepsis detection and prediction
Study NCT00867503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine HCL
Description: bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
Study NCT00719030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate pill
Description: Pomegranate extract pill
Study NCT05431231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Manchester Short Assessment of Quality
Description: a patient questionnaire that assesses quality of life. This questionnaire was developed by Priebe, Huxley, Knight and Evans in 1999. It is based on a longer questionnaire - Lancashire Quality of Life Profile (LQLP) - and was created as an attempt to form an improved shorter version. The questionnaire is composed of two parts: personal details that can change over time and 16 questions that assess objective and subjective quality of life. The objective items are presented as yes or no questions, while regarding the subjective items, participants are asked to describe, using a 7-level Likert scale, the extent to which they are satisfied with their lives. Priebe et al. reported an alpha internal consistency of 0.74.
Study NCT04642118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary recruitment maneuver
Description: Using setting pressure form ventilator to increase pulmonary pressure by compress balloon bag 5 times, 5 seconds per time
Study NCT05431231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Self-Stigma of Mental Illness Scale
Description: a patient questionnaire that assesses internalized self-stigma. It was developed by Corrigan, Watson, and Barr in 2006. The questionnaire is composed of four dimensions. The questionnaire includes 40 items, 10 items for each dimension. The participant is asked to rate the extent to which he agrees with each item using a 9-level Likert scale. The questionnaire yields four separate scores for each dimension, and each dimension can be administered separately and independently. In the current study, only one 10-item dimension will be administered - the extent to which the participant has internalized stereotypes concerning mental illness. Corrigan et al (2006) reported an internal consistency alpha of 0.81 and a test-retest reliability ratio of 0.82 for this dimension.
Study NCT01062789 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optical breath-hold control system (OBC)
Description: The OBC system was designed to replace the IBC rubber bellows respiration sensor system that we are currently using for CT-guided lung biopsies. Unlike the IBC, the OBC is 1) unaffected by temperature changes, 2) has a linear sensitivity (for easier use and better accuracy), 3) has no pneumatic purge time when setting reference breath-hold level (reducing the chance of an inappropriate reference), 4) has no pneumatic cable that can occasionally interfere and get pinched during procedures, 5) is ambulatory (so patients can more easily familiarize themselves with the device before the procedure), 6) is capable of indicating proper fitting tension, 7) allows for easier binding (wireless pairing with other system components), and 8) is significantly less expensive (and possibly disposable).
Study NCT01407952 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HydroCoil Embolic System
Description: HydroCoil Embolic System
Study NCT01407952 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Control (bare platinum coils)
Description: bare platinum coils
Study NCT01547351 — intervention group
Intervention type: OTHER
Intervention: ARMS Questionnaire
Description: The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Eligible patients will be administered part 1 of the survey when the patient presents with new relapse. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
Study NCT00719030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pomegranate pill placebo
Description: Pomegranate pill placebo
Study NCT01054235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Description: The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes).
Study NCT03865368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training
Description: Whole Body Vibration Training (WBVT) method has been used as an alternative to conventional strengthening exercises. In this method, the patient stands on the platform of the WBVT device in a static position or performs dynamic exercises, the mechanical vibration produced by the device is transferred to the body
Study NCT03865368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Vibration Training
Description: Whole Body Vibration Training (WBVT) method has been used as an alternative to conventional strengthening exercises. In this method, the patient stands on the platform of the WBVT device in a static position or performs dynamic exercises, the mechanical vibration produced by the device is transferred to the body
Study NCT01724489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth hormone
Study NCT01724489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01059487 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Chinese Medicine
Description: Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
Study NCT00872638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eversion
Description: Surgical incisions will be closed in such a manner so as to evert the wound edges.
Study NCT00872638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Approximation
Description: Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.
Study NCT02302053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: New Viviscal Professional Supplement
Description: The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
Study NCT02302053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.